Aberdeen Group plc Has $54.04 Million Stake in BioMarin Pharmaceutical Inc. $BMRN

Aberdeen Group plc boosted its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRNFree Report) by 30.2% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 983,048 shares of the biotechnology company’s stock after purchasing an additional 227,773 shares during the quarter. Aberdeen Group plc owned 0.51% of BioMarin Pharmaceutical worth $54,038,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. Dodge & Cox raised its stake in BioMarin Pharmaceutical by 1.4% in the 1st quarter. Dodge & Cox now owns 14,955,240 shares of the biotechnology company’s stock worth $1,057,186,000 after purchasing an additional 209,005 shares in the last quarter. AQR Capital Management LLC raised its stake in BioMarin Pharmaceutical by 127.9% in the 1st quarter. AQR Capital Management LLC now owns 2,925,805 shares of the biotechnology company’s stock worth $203,987,000 after purchasing an additional 1,642,206 shares in the last quarter. Nuveen LLC acquired a new stake in BioMarin Pharmaceutical in the 1st quarter worth about $184,475,000. Goldman Sachs Group Inc. raised its stake in BioMarin Pharmaceutical by 212.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,592,963 shares of the biotechnology company’s stock worth $112,607,000 after purchasing an additional 1,083,512 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in BioMarin Pharmaceutical by 7.6% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 1,532,314 shares of the biotechnology company’s stock worth $108,319,000 after purchasing an additional 108,806 shares in the last quarter. Institutional investors and hedge funds own 98.71% of the company’s stock.

Analyst Ratings Changes

Several analysts have weighed in on the stock. Guggenheim lifted their price objective on shares of BioMarin Pharmaceutical from $101.00 to $106.00 and gave the stock a “buy” rating in a research note on Wednesday, August 6th. Wedbush restated an “outperform” rating and issued a $94.00 target price on shares of BioMarin Pharmaceutical in a research report on Tuesday, August 5th. Weiss Ratings restated a “sell (d+)” rating on shares of BioMarin Pharmaceutical in a research report on Wednesday. Wolfe Research set a $95.00 target price on shares of BioMarin Pharmaceutical and gave the company an “outperform” rating in a research report on Tuesday, July 15th. Finally, JPMorgan Chase & Co. boosted their target price on shares of BioMarin Pharmaceutical from $116.00 to $119.00 and gave the company an “overweight” rating in a research report on Thursday. Thirteen analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, BioMarin Pharmaceutical has a consensus rating of “Moderate Buy” and an average target price of $93.26.

View Our Latest Research Report on BMRN

BioMarin Pharmaceutical Trading Down 2.8%

Shares of BioMarin Pharmaceutical stock opened at $52.32 on Friday. The firm has a market capitalization of $10.05 billion, a PE ratio of 15.53, a price-to-earnings-growth ratio of 0.66 and a beta of 0.33. The company has a current ratio of 5.56, a quick ratio of 3.60 and a debt-to-equity ratio of 0.10. The firm’s 50 day moving average is $56.37 and its 200 day moving average is $58.09. BioMarin Pharmaceutical Inc. has a 1 year low of $51.78 and a 1 year high of $73.51.

BioMarin Pharmaceutical Company Profile

(Free Report)

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

Further Reading

Want to see what other hedge funds are holding BMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioMarin Pharmaceutical Inc. (NASDAQ:BMRNFree Report).

Institutional Ownership by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.